Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Maze Therapeutics, Inc. - Common Stock
(NQ:
MAZE
)
25.93
-0.50 (-1.87%)
Delayed Quote
Updated: 2:03 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Maze Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
↗
October 05, 2026
Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest.
Via
MarketBeat
Gapping stocks in Tuesday's session
↗
September 22, 2026
Via
Chartmill
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
↗
September 11, 2026
The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.
Via
The Motley Fool
Topics
Regulatory Compliance
Stay updated with the stocks that are on the move in today's after-hours session.
↗
September 09, 2026
Via
Chartmill
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
September 02, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Appointments to Its Board of Directors
August 13, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 11, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
↗
June 29, 2026
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
↗
June 05, 2026
This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
May 27, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
↗
May 17, 2026
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Via
The Motley Fool
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 12, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
↗
May 07, 2026
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
↗
April 04, 2026
This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider sale.
Via
The Motley Fool
Topics
Regulatory Compliance
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
March 25, 2026
Via
Chartmill
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
↗
March 25, 2026
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.
Via
The Motley Fool
Topics
Regulatory Compliance
Wednesday's session: top gainers and losers
↗
March 25, 2026
Via
Chartmill
Which stocks are gapping on Wednesday?
↗
March 25, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 25, 2026
Via
Chartmill
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
↗
March 21, 2026
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
↗
February 18, 2026
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise...
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
↗
February 16, 2026
Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
↗
February 01, 2026
Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical...
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150%
↗
January 07, 2026
This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
